Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.
Matthew E StokesKerstin WenzlC Chris HuangMaría OrtizChih-Chao HsuMatthew John MaurerNicholas StongYumi NakayamaLei WuHsiling ChiuAnn PolonskaiaSamuel A DanzigerFadi TowficJoel ParkerRebecca L KingBrian K LinkSusan L SlagerVivekananda SarangiYan W AsmannJoseph P NovakAkshay SudhindraStephen M AnsellThomas M HabermannPatrick R HagnerGrzegorz S NowakowskiJames R CerhanAnne J NovakAnita K GandhiPublished in: Nature communications (2024)
Immunochemotherapy has been the mainstay of treatment for newly diagnosed diffuse large B-cell lymphoma (ndDLBCL) yet is inadequate for many patients. In this work, we perform unsupervised clustering on transcriptomic features from a large cohort of ndDLBCL patients and identify seven clusters, one called A7 with poor prognosis, and develop a classifier to identify these clusters in independent ndDLBCL cohorts. This high-risk cluster is enriched for activated B-cell cell-of-origin, low immune infiltration, high MYC expression, and copy number aberrations. We compare and contrast our methodology with recent DLBCL classifiers to contextualize our clusters and show improved prognostic utility. Finally, using pre-clinical models, we demonstrate a mechanistic rationale for IKZF1/3 degraders such as lenalidomide to overcome the low immune infiltration phenotype of A7 by inducing T-cell trafficking into tumors and upregulating MHC I and II on tumor cells, and demonstrate that TCF4 is an important regulator of MYC-related biology in A7.
Keyphrases
- diffuse large b cell lymphoma
- newly diagnosed
- poor prognosis
- copy number
- epstein barr virus
- end stage renal disease
- ejection fraction
- single cell
- long non coding rna
- chronic kidney disease
- transcription factor
- machine learning
- prognostic factors
- genome wide
- magnetic resonance imaging
- computed tomography
- acute lymphoblastic leukemia
- cell therapy
- stem cell transplantation
- mesenchymal stem cells
- low dose
- multiple myeloma
- binding protein
- replacement therapy